Practical Aspects of Prostaglandin E1 before and after Solid Organ Transplantation
Prostaglandins and analogues for therapeutic use gained importance in the early eighties, when a substantial number of clinical studies about their therapeutical effects was published6, 12, 17, 22. Out of the huge family of prostanoids, prostaglandins E1 (PG E1) and I2 and their synthetical analogues are the most important substances in clinical practice in the field of solid organ transplantation. Organ procurement and organ preservation4, 5, 9, 15, 19 as well as treatment of primary graft failure8, 10 have been described as possible indications for PG E1. Vasodilating effects of prostaglandins are mediated by increasing cAMP levels in vascular smooth muscle cells. This mediation by cAMP is shared with beta-agonists and phosphodiesterase-inhibitors, but not with nitrates and nitric oxide3, 14, 21. Treatment of elevated pulmonary vascular resistance (PVR), which is frequently needed after heart transplantation (HTX), and in the pretransplant evaluation as well as bridging to transplan-tation1, 7, 20 has been the indication for PG E1 in our patient cohort.
KeywordsPulmonary Hypertension Systemic Vascular Resistance Solid Organ Transplantation Primary Pulmonary Hypertension Heart Lung Transplant
Unable to display preview. Download preview PDF.
- 4.Harjula A., Baldwin J. et al, Clinical heart lung preservation with Prostaglandin E1. Transpl Proc. 19: 4101 (1987)Google Scholar
- 8.Iberer F., Müller H. et al., Prostaglandin E1 in der Therapie der Abstoßung und des pulmonalen Hypertonus im Rahmen der Herztransplantation. Immundiagnostik und Immuntherapie in der modernen Intensivmedizin, Vogt S., ed., Pabst-Verlag, Lengerich (1993)Google Scholar
- 11.Murali S., Uretsky B., Armitage J. et al., Utility of Prostaglandin E1 in the Pretransplantation Evaluation of Heart Failure Patients with Significant Pulmonary Hypertension. J Heart Lung Transplant. 11: 716–23(1991)Google Scholar
- 12.Naeije R., Melot C et al., Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Despir Dis. 125: 1–5 (1982)Google Scholar
- 16.Schweer H., Cawello W., Seyberth HW, Gas chromatogryphy negative ion chemical ionization triple quadrupole mass spectometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2, 3, 4, 5, 20-pentanor-19-carboprostanoic acid in plasma. Prostaglandins Leukot Essent Fatty Acids. 51(6): 401–5(1994)PubMedCrossRefGoogle Scholar
- 18.Sorbara C, Pitarello D. et al., Prostaglandine in der Intensivmedizin und bei Herztransplantationen. Translation from A.P.I. C.E; Vol. 8: 327–337 (1993)Google Scholar
- 20.Vincent J., Carlier E. et al., Prostaglandin E1 infusion for right ventricular failure after after cardiac transplantation. J Thorac Cardiovasc Surgery. 103: 33–39 (1992)Google Scholar
- 22.Watkins W., Peterson M. et al., Prostacyclin and Prostaglandin E1 for severe idiopathic pulmonary hypertension. Lancet I. 1083 (1981)Google Scholar